Lee's Pharmaceutical Holdings Limited
李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT – OFFICIAL RELEASE OF THE RESULT OF PHASE I CLINICAL TRIAL ON THE SAFETY AND ANTITHROMBOTIC EFFICACY OF ANFIBATIDE

This announcement is made by the board (the "**Board**") of directors of Lee's Pharmaceutical Holdings Limited (the "**Company**" or "**Lee's Pharm**", together with its subsidiaries as the "**Group**") on a voluntary basis.

The Board of the Company is pleased to announce that the principal findings of the completed phase I clinical trial (clinicaltrials.gov registration number: NCT01588132) which evaluated the anti-thrombotic efficacy and safety of Anfibatide in vitro, ex vivo with human blood, and after injection and infusion in healthy human subjects have recently been published in Scientific Reports on 3 June 2021 in an article titled "In vitro assessment and phase I randomized clinical trial of Anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIbα". The data published therein suggesting that Anfibatide may be a potentially safe and effective agent for anti-thrombotic therapy targeting platelet GPIbα which deserves further investigation. Full version of this article can be found at www.nature.com/articles/s41598-021-91165-8.

Platelet adhesion and aggregation at sites of vascular injury are key events in the arrest of bleeding, but also contribute to vascular thrombosis, such as in the atherosclerotic coronary or cerebral arteries, causing heart attack and stroke, the leading causes of morbidity and mortality worldwide. The interaction of platelet GPIbα with von Willebrand factor ("**VWF**") is essential to initiate platelet adhesion and thrombosis, particularly under high shear stress conditions. However, no drug targeting GPIbα has been developed for clinical practice. Anfibatide, a GPIbα antagonist purified from snake (Deinagkistrodon acutus) venom, is being characterised and evaluated in terms of its interaction with GPIbα by surface plasmon resonance and in silico modeling. It is demonstrated that Anfibatide interfered with both VWF and thrombin binding, inhibited ristocetin/botrocetin- and low-dose thrombin-induced human platelet aggregation, and decreased thrombus volume and stability in blood flowing over collagen.

* *For identification purpose only*

In a single-center, randomised, and open-label phase I clinical trial, Anfibatide was administered intravenously to 94 healthy volunteers either as a single dose bolus, or a bolus followed by a constant rate infusion of Anfibatide for 24 hours. Anfibatide inhibited VWF-mediated platelet aggregation without significantly altering bleeding time or coagulation. The inhibitory effects disappeared within 8 hours after drug withdrawal. No thrombocytopenia or anti-Anfibatide antibodies were detected, and no serious adverse events or allergic reactions were observed during the studies. Therefore, Anfibatide was well tolerated among healthy subjects. In addition, Anfibatide exhibited pharmacologic effects in vivo at concentrations thousand-fold lower than in vitro, a phenomenon which deserves further investigation.

ABOUT ANFIBATIDE

Anfibatide is a new molecular entity discovered and developed by the Group. It is a first-in-class platelet GPIbα receptor antagonist that has fast onset, potent, and reversible anti-thrombotic effect among healthy subjects without impairing coagulation or prolonging bleeding time. Anfibatide has been shown as a promising candidate that could be beneficial for the treatment of ischemic stroke and has a protective effect on cerebral ischemia/reperfusion injury in animal models. Based on the safety profile of Anfibatide in phase I clinical trial, it provides the basis for assessing the non-ST Segment Elevation Myocardial Infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention in the phase Ib-IIa and phase IIb trials. Further studies will be required to define the optimal dosing strategy for patients with acute coronary syndrome, who often have a high intracoronary thrombus burden and may require a higher therapeutic dosage of Anfibatide in order to achieve a higher anti-platelet effect. In addition, Anfibatide effective in treating spontaneous and bacterial shigatoxin-induced TTP in murine model when it is administered at the optimal dosage, route, and interval. In 2016, Anfibatide received orphan drug designation from the U.S. Food and Drug Administration for treatment of thrombotic thrombocytopenic purpura (TTP) in humans. The Group has obtained patents for this product in China and Australia, and several US and European patent applications are currently under examination.

ABOUT SCIENTIFIC REPORTS

Scientific Reports is an open access journal publishing original research from across all areas of the natural sciences, medicine and engineering, and is led by the same ethical and editorial policy guidelines as other Nature Research journals. More information at www.nature.com/srep/about.

ABOUT LEE'S PHARM

Lee's Pharm is a research-driven and market-oriented biopharmaceutical company with more than 25 years of operation in the pharmaceutical industry in China. The Company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives. The Company has established extensive partnerships with over 20 international companies and currently markets 25 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. The Company focuses on several key disease areas such as cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics and urology, and has more than 40 products under different development stages stemming from both internal research and development as well as from the licensing and development, commercialisation, and manufacturing rights from various United States, European and Japanese companies. More information at www.leespharm.com.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 7 June 2021

As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive directors of the Company, Dr. Li Xiaoyi and Mr. Simon Miles Ball are non-executive directors of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.